LABCORP HOLDINGS INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 195.5 USD | +0.29% |
|
-0.39% | -14.02% |
| Sales 2024 * | 12.8B 1,063B | Sales 2025 * | 13.4B 1,113B | Capitalization | 16.43B 1,365B |
|---|---|---|---|---|---|
| Net income 2024 * | 940M 78.08B | Net income 2025 * | 1.08B 89.54B | EV / Sales 2024 * | 1.65 x |
| Net Debt 2024 * | 4.71B 391B | Net Debt 2025 * | 4.17B 347B | EV / Sales 2025 * | 1.54 x |
| P/E ratio 2024 * |
17.1
x | P/E ratio 2025 * |
14.9
x | Employees | 61,975 |
| Yield 2024 * |
1.51% | Yield 2025 * |
1.55% | Free-Float | 99.65% |
More Fundamentals
* Assessed data
More news
Latest transcript on Labcorp Holdings Inc.
More recommendations
More press releases
More news
| 1 day | +0.32% | ||
| 1 week | -0.39% | ||
| Current month | +0.26% | ||
| 1 month | -2.93% | ||
| 3 months | -10.81% | ||
| 6 months | -11.97% | ||
| Current year | -14.02% |
1 week
191.97
199.57
1 month
191.97215.07
Current year
191.97234.09
1 year
191.97243.30
3 years
191.97317.17
5 years
98.02317.17
10 years
95.61317.17
| Managers | Title | Age | Since |
|---|---|---|---|
Adam Schechter
CEO | Chief Executive Officer | 59 | 01/13/01 |
Glenn Eisenberg
DFI | Director of Finance/CFO | 62 | 16/14/16 |
| Compliance Officer | 65 | 01/19/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Adam Schechter
CEO | Chief Executive Officer | 59 | 01/13/01 |
Peter Neupert
BRD | Director/Board Member | 68 | 01/13/01 |
Kerrii Anderson
BRD | Director/Board Member | 66 | 17/06/17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.97% | 2 M€ | -.--% | ||
| 1.95% | 8 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 195.4 | +0.26% | 197 849 |
| 31/24/31 | 194.9 | +0.76% | 1,255,709 |
| 30/24/30 | 193.4 | +0.49% | 1,361,640 |
| 29/24/29 | 192.5 | -1.88% | 942,902 |
| 28/24/28 | 196.2 | -1.73% | 743,619 |
Delayed Quote Nyse, June 03, 2024 at 10:39 pm IST
More quotes
Labcorp Holdings Inc. provides comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company serves clients in more than 100 countries.
Calendar
25/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
194.9
USD
Average target price
238.5
USD
Spread / Average Target
+22.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.02% | 16.43B | |
| +22.01% | 88.99B | |
| -24.22% | 74.82B | |
| +1.06% | 26.63B | |
| +3.92% | 17.88B | |
| +1.94% | 15.77B | |
| +75.88% | 13.21B | |
| +69.59% | 13.08B | |
| +39.32% | 12.9B | |
| +21.90% | 12.7B |
- Stock Market
- Equities
- LH Stock
